Strategic partnership Opportunity to leverage existing collaboration with GE Healthcare for PET imaging agents and immunotherapy diagnostic tools to broaden sales into radiopharmaceuticals, diagnostic services, and integrated therapy-guidance solutions.

Sparse team leverage With a small team (2-10 employees) and meaningful revenue and prior fundraising, there is a need for channel partnerships, contract manufacturing, and sales outsourcing to scale customer reach and accelerate deal closure.

Theranostic expansion PCC technology enables dual roles as diagnostic PET tracers and targeted therapeutics, presenting cross-sell opportunities into oncology drug discovery clients, radiopharma firms, and hospitals seeking precision medicine capabilities.

Focused verticals Target mid-to-large biotech, CROs, and medical imaging providers seeking advanced PET agents and diagnostic tools; align value proposition around accelerated development timelines, specificity, and potential cost savings in patient management.

Funding to deployment Existing Series A and revenue footprint indicate readiness for pilot collaborations, licensing deals, and co-development agreements with larger life sciences players looking to augment their imaging portfolios and companion diagnostics offerings.